Sei Investments Co. Has $5.99 Million Stock Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Sei Investments Co. lessened its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 38.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 494,444 shares of the company’s stock after selling 312,976 shares during the period. Sei Investments Co. owned 0.10% of Elanco Animal Health worth $5,988,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. JPMorgan Chase & Co. lifted its holdings in Elanco Animal Health by 76.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 10,057,656 shares of the company’s stock worth $147,747,000 after buying an additional 4,361,799 shares during the period. Brandes Investment Partners LP lifted its stake in shares of Elanco Animal Health by 66.9% in the fourth quarter. Brandes Investment Partners LP now owns 5,731,180 shares of the company’s stock worth $69,405,000 after acquiring an additional 2,296,691 shares during the period. Magnetar Financial LLC boosted its holdings in Elanco Animal Health by 13.7% in the fourth quarter. Magnetar Financial LLC now owns 12,032,325 shares of the company’s stock valued at $145,711,000 after acquiring an additional 1,454,082 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Elanco Animal Health in the third quarter valued at approximately $19,708,000. Finally, Private Management Group Inc. increased its position in Elanco Animal Health by 63.4% during the 4th quarter. Private Management Group Inc. now owns 2,357,142 shares of the company’s stock valued at $28,545,000 after purchasing an additional 914,808 shares during the period. Institutional investors own 97.48% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Piper Sandler reduced their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, March 6th. Morgan Stanley cut their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 26th. Barclays lowered their price objective on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, February 26th. UBS Group cut their target price on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Finally, Stifel Nicolaus lowered their target price on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a report on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, Elanco Animal Health presently has a consensus rating of “Hold” and an average price target of $15.17.

Elanco Animal Health Stock Performance

Shares of ELAN opened at $10.35 on Wednesday. Elanco Animal Health Incorporated has a one year low of $10.03 and a one year high of $18.80. The company has a market cap of $5.12 billion, a PE ratio of 25.86, a P/E/G ratio of 2.50 and a beta of 1.44. The stock has a 50-day moving average of $11.17 and a 200-day moving average of $12.37. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period last year, the business posted $0.08 EPS. The company’s revenue was down 1.4% on a year-over-year basis. On average, equities research analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Insider Buying and Selling at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius acquired 10,000 shares of the firm’s stock in a transaction on Tuesday, March 11th. The stock was purchased at an average cost of $10.20 per share, with a total value of $102,000.00. Following the acquisition, the director now owns 111,459 shares of the company’s stock, valued at approximately $1,136,881.80. This trade represents a 9.86 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.57% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.